Eyeworld CME Supplements

EW SEP 2017 - Supported by unrestricted educational grants from Allergan, Shire Pharmaceuticals, TearLab, and TearScience

This is a supplement to EyeWorld Magazine that doctors can take a test after reading and receive CME credits for.

Issue link: http://cmesupplements.eyeworld.org/i/863394

Contents of this Issue

Navigation

Page 0 of 7

The third refractive surface: Improving surgical outcomes with advanced diagnostics and therapeutics continued on page 2 Accreditation Statement This activity has been planned and imple- mented in accordance with the accreditation requirements and policies of the Accredi- tation Council for Continuing Medical Edu- cation through the joint providership of the American Society of Cataract and Refractive Surgery (ASCRS) and EyeWorld. ASCRS is accredited by the ACCME to provide continu- ing medical education for physicians. Educational Objectives Ophthalmologists who participate in this activity will: • Improve practice protocols for the screening, diagnosis, and classification of ocular surface disease Designation Statement The American Society of Cataract and Refractive Surgery designates this enduring materials educational activity for a maximum of 1.0 AMA PRA Category 1 Credits. ™ Phy- sicians should claim only credit commensu- rate with the extent of their participation in the activity. Claiming Credit To claim credit, participants must visit bit. ly/2vfjjgk to review content and download the post-activity test and credit claim. All participants must pass the post-activity test with a score of 75% or higher to earn credit. Alternatively, the post-test form included in this supplement may be faxed to the number indicated for credit to be awarded, and a certificate will be mailed within 2 weeks. When viewing online or downloading the material, standard internet access is required. Adobe Acrobat Reader is needed to view the materials. CME credit is valid through February 28, 2018. CME credit will not be awarded after that date. Notice of Off-Label Use Presentations This activity may include presentations on drugs or devices or uses of drugs or devices that may not have been approved by the Food and Drug Administration (FDA) or have been approved by the FDA for specific uses only. ADA/Special Accommodations ASCRS and EyeWorld fully comply with the legal requirements of the Americans with Disabilities Act (ADA) and the rules and regulations thereof. Any participant in this educational program who requires special accommodations or services should contact Laura Johnson at ljohnson@ascrs.org or 703-591-2220. Financial Interest Disclosures Kenneth Beckman, MD, has an investment interest in and has received a retainer, ad hoc fees or other consulting income from Ey- eXpress and RPS. He has received a retainer, ad hoc fees or other consulting income from and is a member of the speakers bureau of: Alcon, Allergan, Shire, Sun Pharma, and TearLab. Dr. Beckman has received a retain- er, ad hoc fees or other consulting income from Bausch + Lomb and TearLab. Eric Donnenfeld, MD, has an investment interest in and has received a retainer, ad hoc fees or other consulting income from: AcuFocus, AqueSys, Elenza, Glaukos, Icon Biosciences, Kala Pharmaceuticals, Katena, Mimetogen, Novabay, Omeros, PRN, and TearLab. He has an investment interest in: LacriScience, Mati, Omega Ophthal- mics, Ocuhub, Pogotec, RPS, Strathspey Crown, TrueVision, and Versant Ventures. Dr. Donnenfeld has received a retainer, ad hoc fees or other consulting income from: Abbott, Alcon, Allergan, Bausch + Lomb, Beaver-Visitec, Foresight, Novaliq, Shire, and TLC Laser Centers. He is a member of the speakers bureaus of: Pfizer, RPS, and TLC Laser Centers, and he has received research funding from: Alcon, Allergan, Bausch + Lomb, Beaver-Visitec, Icon Biosciences, Kala, Omeros, PRN, and Shire. Francis Mah, MD, has an investment inter- est in Sydnexis. He has received a retainer, ad hoc fees or other consulting income from Abbott, Aerie, Alcon, Allergan, Bausch + Lomb, CoDa, NovaBay, Ocular Science, Okogen, Omeros, PollyActiva, Shire, Sun Pharma, TearLab. Dr. Mah is a member of the speakers bureau of: Abbott, Alcon, Allergan, Bausch + Lomb, Shire, and Sun Pharma. He has received research funding from Abbott, Allergan, and Ocular Science. Christopher Starr, MD, has an investment interest in GlassesOff/Innovision and Tear- Lab. He has received a retainer, ad hoc fees or other consulting income from: Allergan, Bausch + Lomb, GlassesOff/Innovision, Re- Focus, RPS, Shire, Sun Pharma, and TearLab. Dr. Starr is a member of the speakers bureau of Alcon, Allergan, and Bausch + Lomb He has received research funding from RPS and travel expense reimbursement from TearLab. Elizabeth Yeu, MD, has an investment interest in Modernizing Medicine and RPS. She has received a retainer, ad hoc fees or other consulting income from and is a member of the speakers bureau of: Abbott, Alcon, Allergan, BioTissue, iOptics, Shire, and TearLab. Dr. Yeu has received a retainer, ad hoc fees or other consulting income from: ArcScan, Bausch + Lomb, Kala, Ocular Therapeutix, OcuSoft, Omeros, and TopCon. She has received research funding from BioTissue, iOptics, and Kala. Staff members: Kristen Covington and Laura Johnson have no ophthalmic-related financial interests. Supplement to EyeWorld September 2017 allows us to examine patients' lids and meibomian glands. Further- more, we can show our findings to patients so they understand their disease, especially if they have no symptoms. we are more likely to diagnose the condition accurately. In addition to point-of- care tests, I use lissamine green staining. We perform dynamic meibomian gland imaging on al- most every surgical candidate and patient with dry eye symptoms. It surgery, refractive cataract sur- geons are less likely to achieve the surgical outcomes patients seek. Diagnostic advances Dry eye is often misdiagnosed, and if patients are treated for the incorrect disease, they will not respond to therapy. To improve treatment, oph- thalmologists need to make the correct diagnosis the first time, but we need to do it simply and efficiently. Point-of-care tests have changed the way we diagnose dry eye. Ophthalmologists should empower technicians to order and perform this testing based on patients' symptoms. Combin- ing these results with our other findings from the examination, Advanced OSD diagnostics and treatments play key role in surgical results P atients older than 70 years have an almost 100% chance of having meibomian gland disease, and many also have aqueous deficiency dry eye. If dry eye remains undiagnosed or is not treated properly before by Eric Donnenfeld, MD Preoperative strategies help clinicians achieve optimal postoperative outcomes Eric Donnenfeld, MD " Refractive cataract surgeons cannot perform premium surgery without a premium ocular surface. " —Eric Donnenfeld, MD Supported by unrestricted educational grants from Allergan, Shire Pharmaceuticals, TearLab, and TearScience Click to read and claim CME credit

Articles in this issue

Links on this page

Archives of this issue

view archives of Eyeworld CME Supplements - EW SEP 2017 - Supported by unrestricted educational grants from Allergan, Shire Pharmaceuticals, TearLab, and TearScience